Walleye Capital LLC Apellis Pharmaceuticals, Inc. Put Options Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $46,144 - $65,840	-1,600 Reduced 88.89%	200 $5,000
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $966,978 - $1.52 Million	-25,400 Reduced 93.38%	1,800 $69,000
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $553,900 - $724,700	10,000 Added 58.14%	27,200 $1.6 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $3,714 - $6,481	-100 Reduced 0.58%	17,200 $1.03 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $210,485 - $794,058	8,900 Added 105.95%	17,300 $658,000
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $467,748 - $569,191	6,100 Added 265.22%	8,400 $765,000
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $316,812 - $455,327	-6,800 Reduced 74.73%	2,300 $151,000
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $337,272 - $476,112	7,800 Added 600.0%	9,100 $470,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $58,188 - $90,558	1,300 New	1,300 $89,000
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $362,080 - $561,954	-14,600 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $261,486 - $647,218	14,600 New	14,600 $391,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.